<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039078</url>
  </required_header>
  <id_info>
    <org_study_id>PCI-IRB-0611014</org_study_id>
    <secondary_id>CDR0000069336</secondary_id>
    <secondary_id>PCI-IRB-000656</secondary_id>
    <secondary_id>PCI-IRB-000871</secondary_id>
    <secondary_id>NCI-V02-1701</secondary_id>
    <nct_id>NCT00039078</nct_id>
  </id_info>
  <brief_title>Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>The Use of TheraSphere® for the Treatment of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allan Tsung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near&#xD;
      a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be&#xD;
      effective treatment for liver cancer that cannot be removed by surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of hepatic arterial infusion using&#xD;
      yttrium-90 microspheres (TheraSphere®) to see how well it works in treating patients with&#xD;
      liver cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Provide supervised access to yttrium-90 glass microspheres (TheraSphere®) for patients&#xD;
           with unresectable hepatocellular carcinoma.&#xD;
&#xD;
        -  Determine the response in patients with unresectable hepatocellular carcinoma treated&#xD;
           with hepatic arterial infusion of yttrium-90 glass microspheres.&#xD;
&#xD;
        -  Determine the toxic effects and adverse experiences associated with this therapy in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the survival time of patients treated with this therapy.&#xD;
&#xD;
        -  Determine the time to progression of disease in the liver, duration of response, and&#xD;
           progression-free interval of patients treated with this therapy.&#xD;
&#xD;
        -  Evaluate the influence of pretreatment characteristics on efficacy parameters in&#xD;
           patients treated with this therapy.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this therapy.&#xD;
&#xD;
      OUTLINE: Radioactive material yttrium-90 glass microspheres (TheraSphere®) is infused&#xD;
      directly into a liver tumor in order to kill tumor cells and cause less damage to the normal&#xD;
      tissue. Patients receive TheraSphere® via hepatic arterial infusion on day 1. This artery is&#xD;
      accessed through the femoral artery in the groin. This procedure is generally completed on an&#xD;
      outpatient basis. Patients may receive a single dose to the whole liver, or sequential&#xD;
      treatments to each side of the liver approximately 30 to 90 days apart. Patients may be&#xD;
      re-treated at a later time.&#xD;
&#xD;
      Patients are followed every 2 to 4 months for the rest of their lives to access tumor&#xD;
      progression, symptom management and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Record created in error - not a research study&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date>August 2000</completion_date>
  <primary_completion_date>August 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time from treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse experiences</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 glass microspheres</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of hepatocellular carcinoma (HCC)&#xD;
&#xD;
               -  Histopathology confirmation may be waived in patients with a radiographically&#xD;
                  identifiable liver mass in addition to known laboratory or clinical risk factors&#xD;
                  for HCC, and/or an elevated alpha-fetoprotein (AFP) level&#xD;
&#xD;
          -  No significant extrahepatic disease that may represent an imminent life-threatening&#xD;
             outcome&#xD;
&#xD;
          -  No evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of&#xD;
             radiotherapy to the lungs on either the first yttrium-90 glass microspheres&#xD;
             (TheraSphere®) administration or with cumulative delivery of radiation to the lungs&#xD;
             over multiple treatments due to any angiographically uncorrectable flow to the&#xD;
             gastrointestinal tract&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No hepatic dysfunction&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  No vascular abnormalities or severe peripheral vascular disease that would preclude&#xD;
             angiography or selective visceral catheterization&#xD;
&#xD;
          -  No pulmonary insufficiency&#xD;
&#xD;
          -  No evidence of detectable technetium Tc 99m macroaggregates of albumin flow to the&#xD;
             stomach or duodenum after application of established angiographic techniques to stop&#xD;
             such flow&#xD;
&#xD;
          -  No contraindications to angiography&#xD;
&#xD;
          -  No contraindications to selective visceral catheterization&#xD;
&#xD;
          -  No other condition or cormorbidity that would preclude study treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 30 days&#xD;
             after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 1 month since prior chemotherapy, radiotherapy, or surgery&#xD;
&#xD;
          -  No other concurrent investigational agents or anticancer therapy for HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T. Clark Gamblin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UPMC Cancer Center at UPMC Presbyterian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Liver Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203.</citation>
    <PMID>15713920</PMID>
  </reference>
  <reference>
    <citation>Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205.</citation>
    <PMID>15508085</PMID>
  </reference>
  <reference>
    <citation>Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9. Review.</citation>
    <PMID>12354840</PMID>
  </reference>
  <results_reference>
    <citation>Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10.</citation>
    <PMID>14762849</PMID>
  </results_reference>
  <results_reference>
    <citation>Carr BI, Sheetz M, Brown M, et al.: Hepatic arterial 90yttrium-labeled glass microspheres (Therasphere) as treatment for unresectable HCC in forty three patients. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-553, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Carr BI, Brown M, France M, et al.: 90 yttrium labeled glass microspheres in the treatment of hepatocellular carcinoma: initial US experience. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-2346, 2001.</citation>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Allan Tsung</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

